The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 05, 2026
Filed:
Sep. 24, 2021
Applicant:
Industry-university Cooperation Foundation Hanyang University Erica Campus, Ansan-si, KR;
Inventors:
Jung-Mi Hah, Ansan-si, KR;
Da Seul Im, Ansan-si, KR;
Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); C07D 239/72 (2006.01); C07D 239/74 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 403/10 (2006.01); C07D 405/10 (2006.01); C07D 413/04 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 239/74 (2013.01); C07D 239/72 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/10 (2013.01); C07D 405/10 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01);
Abstract
The present invention relates to a novel quinazoline derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and a use thereof. A novel quinazoline derivative or a pharmaceutically acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity against FLT3, and thus targeted treatment through more fundamental approaches is expected in the prevention or treatment of acute myeloid leukemia (AML).